Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Boehringer Ingelheim International Gmbh
Boehringer Ingelheim International Gmbh x26 Co Kg
Boehringer Ingelheim International Gmbh Vitae Pharmaceuticals
Boehringer Ingelheim International Gmbh_20100107
Boehringer Ingelheim International Gmbh_20100121
Boehringer Ingelheim International Gmbh_20131212
Boehringer Ingelheim International Gmbh_20100128
Boehringer Ingelheim International Gmbh_20100114

Boehringer Ingelheim International Gmbh patents


Recent patent applications related to Boehringer Ingelheim International Gmbh. Boehringer Ingelheim International Gmbh is listed as an Agent/Assignee. Note: Boehringer Ingelheim International Gmbh may have other listings under different names/spellings. We're not affiliated with Boehringer Ingelheim International Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Boehringer Ingelheim International Gmbh-related inventors


 new patent  Pharmaceutical composition, methods for treating and uses thereof

wherein R1 to R6, and X are as defined herein, and an SGLT2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized... Boehringer Ingelheim International Gmbh

 new patent  Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof

The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.... Boehringer Ingelheim International Gmbh

 new patent  Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction

The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a... Boehringer Ingelheim International Gmbh

 new patent  Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (TPSA) of at least 145, wherein R1, R2, R3, R4, X, and Z− have one of the meanings as defined in the specification,... Boehringer Ingelheim International Gmbh

 new patent  Methods of treating diseases

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.... Boehringer Ingelheim International Gmbh

Polymorphs

The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.... Boehringer Ingelheim International Gmbh

Cyclic dinucleotide compounds

wherein the groups R1, R2 and R3 are defined as in claim 1, which have valuable pharmacological properties, particularly are modulators of STING.... Boehringer Ingelheim International Gmbh

Acylated glucagon analogue

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared... Boehringer Ingelheim International Gmbh

Substituted 3-haloallylamine inhibitors of ssao and uses thereof

The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.... Boehringer Ingelheim International Gmbh

Combination treatment of cancer comprising egfr/her2 inhibitors

optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.... Boehringer Ingelheim International Gmbh

Heteroaromatic compounds as btk inhibitors

wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.... Boehringer Ingelheim International Gmbh

Amylin analogues

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration... Boehringer Ingelheim International Gmbh

Pyridine and pyrazine compounds as inhibitors of ripk2

or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes... Boehringer Ingelheim International Gmbh

Heteroaryl carboxamide compounds as inhibitors of ripk2

or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes... Boehringer Ingelheim International Gmbh

Heteroaryl syk inhibitors

R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.... Boehringer Ingelheim International Gmbh

Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.... Boehringer Ingelheim International Gmbh

Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents

The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML.... Boehringer Ingelheim International Gmbh

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).... Boehringer Ingelheim International Gmbh

New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R9, X1 and X2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer,... Boehringer Ingelheim International Gmbh

Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors

wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic... Boehringer Ingelheim International Gmbh

Immeadiate release oral tablet

A process for the preparation of an immediate release tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.... Boehringer Ingelheim International Gmbh

New azabenzimidazole derivatives as agonists of the amp-activated protein kinase

The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of... Boehringer Ingelheim International Gmbh

Heteroaromatic compounds as btk inhibitors

wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.... Boehringer Ingelheim International Gmbh

Cx3cr1-binding polypeptides

The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such... Boehringer Ingelheim International Gmbh

Compounds as modulators of ror gamma

wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.... Boehringer Ingelheim International Gmbh

6-alkynyl-pyridine derivatives

An exemplary compound is... Boehringer Ingelheim International Gmbh

Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein R1, R2, R3, R4, X, and Z have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical... Boehringer Ingelheim International Gmbh

Methods of treating diseases

This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.... Boehringer Ingelheim International Gmbh

Oral disintegrating tablet

A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.... Boehringer Ingelheim International Gmbh

Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases

The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein R1, R2, R3, R4, X, and Z have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical... Boehringer Ingelheim International Gmbh

2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors

The present invention relates to compounds of formula (I) or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (TPSA) of at least 145, wherein R1, R2, R3, R4, X, and Z− have one of the meanings as defined in the specification,... Boehringer Ingelheim International Gmbh

New azabenzimidazole derivatives

The present invention relates to compounds of general formula (I), wherein R1, R2, R3, A1, A2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and... Boehringer Ingelheim International Gmbh

Novel propellant containing preparations for tiotropium

The present invention relates to a novel propellant-gas-containing medicament composition based on tiotropium 1, processes for the preparation thereof and the use of such medicament compositions in the treatment of respiratory complaints.... Boehringer Ingelheim International Gmbh

Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.... Boehringer Ingelheim International Gmbh

Medical use of pharmaceutical combination or composition

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.... Boehringer Ingelheim International Gmbh

11/30/17 / #20170340643

Vasoprotective and cardioprotective antidiabetic therapy

The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.... Boehringer Ingelheim International Gmbh

11/23/17 / #20170333465

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.... Boehringer Ingelheim International Gmbh

11/23/17 / #20170334995

Antibody molecules for cancer treatment

The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of... Boehringer Ingelheim International Gmbh

11/16/17 / #20170326150

Stable powder formulation containing an anticholingeric agent

A spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X− is a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides,... Boehringer Ingelheim International Gmbh

11/16/17 / #20170327483

Pyridinyl derivatives, pharmaceutical compositions and uses thereof

wherein R1 and A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Boehringer Ingelheim International Gmbh

11/09/17 / #20170319480

Pharmaceutical formulation

The present invention relates to pharmaceutical formulations of highly active drugs with limited shelf-life in aqueous media, suitable to be administered by a caregiver person to a patient avoiding or minimizing the risk of exposure, contact or contamination of the caregiver person with the active product ingredient (API), preferably an... Boehringer Ingelheim International Gmbh

11/09/17 / #20170320838

Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists

The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of... Boehringer Ingelheim International Gmbh

11/09/17 / #20170320867

Heteroaromatic compounds as btk inhibitors

wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.... Boehringer Ingelheim International Gmbh

11/02/17 / #20170312287

Dpp iv inhibitor formulations

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.... Boehringer Ingelheim International Gmbh

11/02/17 / #20170312360

Method for egfr directed combination treatment of cancer

The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50... Boehringer Ingelheim International Gmbh

11/02/17 / #20170313732

Novel annelated phenoxyacetamides

wherein R1, R2, R3, and Z have one of the meanings as indicated in the specification or a pharmaceutically acceptable salt thereof, to the use of compounds of formula (I) as a medicament, to pharmaceutical compositions comprising at least one compound of formula (I), as well as to medicament combinations... Boehringer Ingelheim International Gmbh

10/26/17 / #20170305952

Pharmaceutical composition, methods for treating and uses thereof

The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or... Boehringer Ingelheim International Gmbh

10/19/17 / #20170298053

Novel n-[(pyrimidinylamino)propanyl]-and n [(pyrazinylamino)propanyl]arylcarboxamides

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.... Boehringer Ingelheim International Gmbh

10/19/17 / #20170298126

Methods of treating inflammatory diseases

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.... Boehringer Ingelheim International Gmbh

10/19/17 / #20170298135

Anti il-36r antibodies

... Boehringer Ingelheim International Gmbh

09/21/17 / #20170266152

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.... Boehringer Ingelheim International Gmbh

09/21/17 / #20170266160

Methods for treating pulmonary emphysema using substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c

and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.... Boehringer Ingelheim International Gmbh

09/21/17 / #20170267688

Aldosterone synthase inhibitors

The present invention relates to compounds of the formulas (IA) and (IB) and pharmaceutically acceptable salts thereof, wherein A and R1-R6, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for... Boehringer Ingelheim International Gmbh

08/31/17 / #20170247161

Method and system for calculating a suitability indicator

Methods and systems for calculating a suitability indicator which corresponds to a suitability of a packaging system for packaging a substance, where a stability indicator which corresponds to a stability of the substance or of a component of the substance is determined as a function of at least one ambient... Boehringer Ingelheim International Gmbh

08/31/17 / #20170247315

Novel process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione

This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.... Boehringer Ingelheim International Gmbh

08/31/17 / #20170247394

Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents... Boehringer Ingelheim International Gmbh

08/31/17 / #20170247475

Bispecific binding molecules binding to vegf and ang2

Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic... Boehringer Ingelheim International Gmbh

08/24/17 / #20170239191

Pharmaceutical dosage form for immediate release of an indolinone derivative

The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.... Boehringer Ingelheim International Gmbh

08/03/17 / #20170216298

Beta2-adrenoceptor agonist for the treatment of cough

for use in a method of treatment of cough from various origins.... Boehringer Ingelheim International Gmbh

07/27/17 / #20170209892

Nebulizer

A nebulizer for nebulizing a liquid from a container is proposed. The nebulizer comprises a liquid pump for withdrawing the liquid in doses from the container and pressurizing the respective doses for nebulization. The nebulizer comprises in addition an air pump for temporarily pressurizing the liquid in the container to... Boehringer Ingelheim International Gmbh

07/27/17 / #20170211048

Enhanced reprogramming to ips cells

The present invention concerns a method of preparing a population of iPS cells comprising reducing the amount and/or activity of one or more components of the CAF1 complex, and/or one or more components of the SUMO pathway, in a population of target cells, and (ii) optionally isolating the iPS cells... Boehringer Ingelheim International Gmbh

07/20/17 / #20170203056

Drug delivery device

A drug delivery device (100), in particular a nebulizer or inhaler, is proposed, wherein a collapsible container (16) is combined with a mechanism (30) to help the collapsing process and to prevent the collapsed container expanding again, hence preventing forming of vapor and gas bubbles within.... Boehringer Ingelheim International Gmbh

07/06/17 / #20170189330

Cough syrup containing ambroxol hydrochloride

The present invention relates to cough syrups containing ambroxol hydrochloride, characterised in that they are substantially free from glycerol, and their use for mucolytic treatment in acute and chronic diseases of the bronchi and/or lungs.... Boehringer Ingelheim International Gmbh

07/06/17 / #20170189437

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight,... Boehringer Ingelheim International Gmbh

06/22/17 / #20170173023

Combination therapy with volasertib

Disclosed is the use of Volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising administering a high dose of Volasertib in combination with fludarabine, cytarabine and Granulocyte colony-stimulating factor (GCSF) or in combination with fludarabine, cytarabine, GCSF and a daunorubicin citrate... Boehringer Ingelheim International Gmbh

Patent Packs
06/22/17 / #20170173027

Antidiabetic medications

Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.... Boehringer Ingelheim International Gmbh

06/22/17 / #20170174663

Heteroaromatic compounds as btk inhibitors

wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.... Boehringer Ingelheim International Gmbh

06/22/17 / #20170174695

New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention... Boehringer Ingelheim International Gmbh

06/22/17 / #20170174762

Biparatopic polypeptides antagonizing wnt signaling in tumor cells

The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment... Boehringer Ingelheim International Gmbh

06/08/17 / #20170157130

Treatment of myelodysplastic syndrome

The present invention relates to the use of Volasertib or a pharmaceutically acceptable salt thereof or the hydrate thereof for treating myelodysplastic syndrome (MDS).... Boehringer Ingelheim International Gmbh

06/08/17 / #20170157158

Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii

The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).... Boehringer Ingelheim International Gmbh

06/08/17 / #20170157159

Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i

The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).... Boehringer Ingelheim International Gmbh

06/08/17 / #20170157246

Biomarkers useful in the treatment of il-23a related diseases

This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.... Boehringer Ingelheim International Gmbh

06/01/17 / #20170151249

Combination therapy

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.... Boehringer Ingelheim International Gmbh

05/11/17 / #20170128680

System with nebulizer and container

A system with a nebulizer as well as a container with a fluid and an indicator device for such a nebulizer are proposed. A check scheme is used for indicating the number of containers already used with the nebulizer or which still can be used with the nebulizer. The indicator... Boehringer Ingelheim International Gmbh

05/11/17 / #20170128681

Nebulizer and container

A nebulizer as well as a container with a fluid for such a nebulizer are proposed. The container comprises a control device which indicates initially an unused state of the container before first use. An indicator device stops via a locking device further use of the container in a locked... Boehringer Ingelheim International Gmbh

05/11/17 / #20170129872

Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines

The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.... Boehringer Ingelheim International Gmbh

05/04/17 / #20170119773

Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.... Boehringer Ingelheim International Gmbh

04/27/17 / #20170112835

Quinazoline derivatives for the treatment of cancer diseases

wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.... Boehringer Ingelheim International Gmbh

04/20/17 / #20170106009

Methods of treating diseases

The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.... Boehringer Ingelheim International Gmbh

Patent Packs
04/20/17 / #20170107281

Ang2-binding molecules

Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.... Boehringer Ingelheim International Gmbh

04/13/17 / #20170101411

Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.... Boehringer Ingelheim International Gmbh

04/06/17 / #20170095423

Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets

The present invention relates inter alia to the use of selectively moisture-adjusted tabletting material in the preparation of mechanically stable oral tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing oral tablets.... Boehringer Ingelheim International Gmbh

04/06/17 / #20170095424

Pharmaceutical composition and uses thereof

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.... Boehringer Ingelheim International Gmbh

03/30/17 / #20170087160

Uses of dpp iv inhibitors

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is... Boehringer Ingelheim International Gmbh

03/30/17 / #20170088609

Anticancer combination therapy

The invention describes anti-cancer therapies comprising using a 3G-EGFR inhibitor and an anti-IGF antibody, each as described herein.... Boehringer Ingelheim International Gmbh

03/30/17 / #20170088617

Cd33 binding agents

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).... Boehringer Ingelheim International Gmbh

03/23/17 / #20170079980

Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient

The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by... Boehringer Ingelheim International Gmbh

03/23/17 / #20170081329

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).... Boehringer Ingelheim International Gmbh

03/23/17 / #20170081402

Methods of treating inflammatory diseases

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.... Boehringer Ingelheim International Gmbh

03/16/17 / #20170072001

Fast dissolving granulate

The invention relates to a fast dissolving granulate obtainable by spray-dying of a composition comprising a dry methanolic or ethanolic extract of valerian root, a dry methanolic extract of hop strobiles, optionally a carrier, one or more artificial sweeteners, one or more flavoring agents, optionally an acidifier and water for... Boehringer Ingelheim International Gmbh

03/16/17 / #20170072147

Nebulizer

A nebulizer comprises a replaceable container with fluid to be nebulized. The container comprises an inseparable indicator device. The container and the indicator device are axially moved during nebulization and tensioning of the nebulizer. The indicator device controls locking of the nebulizer against further use if a predetermined number of... Boehringer Ingelheim International Gmbh

03/16/17 / #20170072148

Nebulizer and container

A nebulizer and a container with a fluid for such a nebulizer are proposed. The container comprises an indicator device fixedly mounted on the bottom of the container. When a predetermined number of uses of the container (3) with the nebulizer (1) has been reached or exceeded, a signal element... Boehringer Ingelheim International Gmbh

03/16/17 / #20170072149

Nebulizer

A nebulizer is proposed which receives a container with a fluid and an indicator device. The indicator device stops further use of the container in a locked state when a predetermined number of uses has been reached or exceeded. In the locked state, a locking device locks the nebulizer against... Boehringer Ingelheim International Gmbh

03/16/17 / #20170073333

New pyrazolyl-substituted heteroaryls and their use as medicaments

and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.... Boehringer Ingelheim International Gmbh

03/16/17 / #20170073352

Novel substituted spirocycles

wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.... Boehringer Ingelheim International Gmbh

03/09/17 / #20170065529

Pharmaceutical dosage form for immediate release of an indolinone derivative

The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.... Boehringer Ingelheim International Gmbh

03/09/17 / #20170065595

Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with... Boehringer Ingelheim International Gmbh

03/09/17 / #20170065596

Cardio- and renoprotective antidiabetic therapy

The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.... Boehringer Ingelheim International Gmbh

03/02/17 / #20170058038

Use of anti-cd40 antibodies for treatment of lupus nephritis

The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.... Boehringer Ingelheim International Gmbh

03/02/17 / #20170058039

Anti-cd40 antibodies

The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.... Boehringer Ingelheim International Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Boehringer Ingelheim International Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Boehringer Ingelheim International Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###